HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

Cancer Cell

Volumn 19, Issue 1, 2011, Pages 31-44

  Rolny, Charlotte ^a,b,c   Mazzone, Massimiliano ^b,c   Tugues, Sònia ^a   Laoui, Damya ^b,d   Johansson, Irja ^a   Coulon, Cathy ^b,c   Squadrito, Mario Leonardo ^e   Segura, Inmaculada ^b,c   Li, Xiujuan ^a   Knevels, Ellen ^b,c   Costa, Sandra ^b,c   Vinckier, Stefan ^b,c   Dresselaer, Tom ^f   Åkerud, Peter ^g   De Mol, Maria ^b,c   Salomäki, Henriikka ^a   Phillipson, Mia ^h   Wyns, Sabine ^b,c   Larsson, Erik ^a   Buysschaert, Ian ^b,c   Botling, Johan ^a   Himmelreich, Uwe ^f   Van Ginderachter, Jo A ^b,d   De Palma, Michele ^e   Dewerchin, Mieke ^b,c   Claesson Welsh, Lena ^a   Carmeliet, Peter ^b,c   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f KU Leuven   (Belgium)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN; HISTONE RICH GLYCOPROTEIN; LENTIVIRUS VECTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; MACROPHAGE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

EID: 78651461701     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.11.009     Document Type: Article

References (36)

1. Arteta B., Lasuen N., Lopategi A., Sveinbjornsson B., Smedsrod B., Vidal-Vanaclocha F. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology 2010, 51:2172-2182.
2. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
3. Blank M., Shoenfeld Y. Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems. Clin. Rev. Allergy Immunol. 2008, 34:307-312.
4. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
5. Coenegrachts L., Maes C., Torrekens S., Van Looveren R., Mazzone M., Guise T.A., Bouillon R., Stassen J.M., Carmeliet P., Carmeliet G. Anti-PlGF reducses bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res. 2010, 70:6537-6547.
6. De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007, 28:519-524.
7. De Palma M., Mazzieri R., Politi L.S., Pucci F., Zonari E., Sitia G., Mazzoleni S., Moi D., Venneri M.A., Indraccolo S., et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008, 14:299-311.
8. DeNardo D.G., Andreu P., Coussens L.M. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010, 29:309-316.
9. Dixelius J., Olsson A.K., Thulin A., Lee C., Johansson I., Claesson-Welsh L. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res. 2006, 66:2089-2097.
10. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
11. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
12. Guan X., Juarez J.C., Qi X., Shipulina N.V., Shaw D.E., Morgan W.T., McCrae K.R., Mazar A.P., Donate F. Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb. Haemost. 2004, 92:403-412.
13. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., Robinson S.C., Balkwill F.R. " Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008, 205:1261-1268.
14. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., Rabie T., Kaden S., Grone H.J., Hammerling G.J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
15. Hedlund E.M., Hosaka K., Zhong Z., Cao R., Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. USA 2009, 106:17505-17510.
16. Hulett M.D., Parish C.R. Murine histidine-rich glycoprotein: cloning, characterization and cellular origin. Immunol. Cell Biol. 2000, 78:280-287.
17. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
18. Jones A.L., Hulett M.D., Parish C.R. Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation. J. Biol. Chem. 2004, 279:30114-30122.
19. Jones A.L., Hulett M.D., Parish C.R. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol. Cell Biol. 2005, 83:106-118.
20. Kampf G., Ostermeyer C. Influence of applied volume on efficacy of 3-minute surgical reference disinfection method prEN 12791. Appl. Environ. Microbiol. 2004, 70:7066-7069.
21. Karrlander M., Lindberg N., Olofsson T., Kastemar M., Olsson A.K., Uhrbom L. Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. PLoS ONE 2009, 4:e8536.
22. Klenotic P.A., Huang P., Palomo J., Kaur B., Van Meir E.G., Vogelbaum M.A., Febbraio M., Gladson C.L., Silverstein R.L. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am. J. Pathol. 2010, 176:2039-2050.
23. Koppelman B., Neefjes J.J., de Vries J.E., de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997, 7:861-871.
24. Lewis C.E., De Palma M., Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 2007, 67:8429-8432.
25. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
26. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
27. Mazzone M., Dettori D., Leite de Oliveira R., Loges S., Schmidt T., Jonckx B., Tian Y.M., Lanahan A.A., Pollard P., Ruiz de Almodovar C., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
28. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70:5728-5739.
29. Olsson A.K., Larsson H., Dixelius J., Johansson I., Lee C., Oellig C., Bjork I., Claesson-Welsh L. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res. 2004, 64:599-605.
30. Poon I.K., Hulett M.D., Parish C.R. Histidine-rich glycoprotein is a novel plasma pattern recognition molecule that recruits IgG to facilitate necrotic cell clearance via FcgammaRI on phagocytes. Blood 2010, 115:2473-2482.
31. Poon I.K., Parish C.R., Hulett M.D. Histidine-rich glycoprotein functions cooperatively with cell surface heparan sulfate on phagocytes to promote necrotic cell uptake. J. Leukoc. Biol. 2010, 88:559-569.
32. Pucci F., Venneri M.A., Biziato D., Nonis A., Moi D., Sica A., Di Serio C., Naldini L., De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood " resident" monocytes and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
33. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
34. Simantov R., Febbraio M., Crombie R., Asch A.S., Nachman R.L., Silverstein R.L. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J. Clin. Invest. 2001, 107:45-52.
35. Thulin A., Ringvall M., Dimberg A., Karehed K., Vaisanen T., Vaisanen M.R., Hamad O., Wang J., Bjerkvig R., Nilsson B., et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol. Cancer Res. 2009, 7:1792-1802.
36. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.